USPTO serial 97782706
FORTREA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 24, 2026
- Examiner
- DIGAN, MATTHEW M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with FORTREA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Durham, NC, US
DURHAM, NC, US
DURHAM, NC, US
DURHAM, NC, US
DURHAM, NC, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Laura C. Miller
Laura C. Miller KILPATRICK TOWNSEND & STOCKTON LLP1001 WEST FOURTH STREETWinston-Salem, NC 27101United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business consulting, management, and planning services in the field of clinical trials; regulatory submission management, namely, assisting others in preparing and filing applications with governmental regulatory bodies for approval and post-approval actions related to drugs and medical devices; economic forecasting and analysis in the field of pharmaceutical, biotechnology, and medical device industries; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; business management services, namely, supply and demand forecasting in connection with drug supplies for clinical trials; recruitment advertisement services, namely, posting of clinical trial notices for the purpose of recruiting patients and volunteers for participation in clinical trials for the testing of drugs; business administration of patient reimbursement programs; business advisory services, business consultancy services, business data analysis, business information services, business management consulting, business strategy development services, market intelligence services, market research, marketing services, electronic data collection and data submission services for business purposes, database management, business project management services all in the fields of clinical trials and post approval pharmaceuticals, medical devices, and biotechnology; market research and business marketing consulting services in the fields of international health and pharmaceutical, biotechnology, and medical device industries; market analysis in the field of international health and in the pharmaceutical, biotechnology, and medical device industries; providing business and statistical information for business purposes and data processing services, all in the field of international health and in the pharmaceutical, biotechnology, and medical device industries | ACTIVE | Feb 9, 2023 |
| 042 | Pharmaceutical drug development services; design and testing of new products, namely, medical devices, for others; research and development in the fields of pharmaceuticals, medical devices, and biotechnology; medical and scientific research in the field of clinical trials, namely, designing, organizing, conducting, monitoring, and managing clinical trials and studies on pharmaceuticals and medical devices for others; scientific consulting services for others in the field of design, planning, and implementation project management of clinical trials and studies on pharmaceuticals and medical devices; providing temporary use of online non-downloadable software for the collection, calibration, analysis and reporting of medical and scientific research data in connection with clinical trials and studies on pharmaceuticals and medical devices; scientific laboratory services; scientific laboratory services, namely, formulating and bioprocessing pharmaceuticals; rental of laboratory apparatus and instruments; database design and development in the field of pharmaceutical drug development and medical device testing services; design and development of software for use in conducting research in pharmaceutical and medical device development studies; providing online computer databases in the fields of research and development of pharmaceuticals, medical devices, and biotechnology; data mining in the fields of research and development of pharmaceuticals, medical devices, and biotechnology; providing a website featuring technology enabling users to remotely track, monitor, analyze, and generate reports with information and statistics from clinical trials and studies on pharmaceuticals and medical devices; advisory services for others in the field of pharmaceutical drug development; providing medical and scientific research information in the fields of biochemistry, pharmaceuticals and clinical trials; providing online non-downloadable software for tracking, monitoring, analyzing, generating and reporting information and statistics about patient reimbursement and insurance coverage for pharmaceuticals and medical devices; application service provider (ASP) featuring software for use in database and record management in the fields of clinical trials and post-approval research for pharmaceuticals and medical devices; providing temporary use of online non downloadable software for collecting, organizing, and reporting clinical trial information and trial results; providing temporary use of online non-downloadable software for uploading and accessing test results in the field of medical testing for scientific research purposes; providing temporary use of online non-downloadable software for storing, retrieving, accessing, displaying, managing, analyzing, and reviewing information and data in the fields of pharmaceuticals, medical devices, and biotechnology; scientific study and research in the field of production of pharmaceuticals and medical devices; providing online non-downloadable software for planning, managing and supporting clinical trials; medical and scientific clinical research for others in the field of the production of pharmaceuticals, biopharmaceuticals, and medical devices; software as a service (SAAS) services, namely, hosting software for use by others for the collection, review, analysis, and reporting of clinical trial and drug development information; research and development in the field of pharmaceuticals, biopharmaceuticals, medical devices, and medical diagnostics; clinical research in the field of production of pharmaceuticals, medical devices and medical diagnostics; providing interactive web sites featuring technology that enables users to collect, review, analyze and report on clinical research and drug development information; providing temporary use of online non downloadable software to allow users to collect, review, analyze and report on clinical research and drug development | ACTIVE | Feb 9, 2023 |
| 044 | Medical services in the field of pharmacology and specimen collection and procedures in connection with clinical trials; providing an online computer database featuring medical information in the field of patient management and outcomes; providing a website featuring medical information in the fields of clinical trials and patient management and outcomes; medical and pharmaceutical consultation | ACTIVE | Feb 9, 2023 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Labcorp Drug Development Inc.
- Other trademarks owned by FORTREA INC.
- Other trademarks owned by FORTREA INC.
- Other trademarks owned by FORTREA INC.
- Other trademarks owned by FORTREA INC.
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named FORTREA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 7, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 24, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 24, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 3, 2026 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Mar 3, 2026 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Mar 2, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Mar 2, 2026 | IULN | ITU LETTER MAILED, NO RESPONSE REQUIRED | — |
| Jan 23, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 24, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 23, 2025 | IUAF | USE AMENDMENT FILED | — |
| Jul 23, 2025 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jul 23, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 23, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 23, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 4, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 23, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 23, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 23, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 23, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 28, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 28, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 8, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 19, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 19, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 19, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 19, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 19, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 18, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 17, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 17, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 14, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 14, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 14, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 9, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 9, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 9, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 2, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 7, 2023 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Feb 25, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Feb 24, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 9, 2023 | NWAP | NEW APPLICATION ENTERED | — |